Immuneering Co. (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Brokerages

Immuneering Co. (NASDAQ:IMRX - Get Free Report) has received an average rating of "Moderate Buy" from the eight ratings firms that are covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $13.50.

Several research analysts have issued reports on the company. Chardan Capital dropped their price objective on Immuneering from $21.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, March 15th. Guggenheim reiterated a "neutral" rating on shares of Immuneering in a research report on Thursday, March 14th. Mizuho reduced their price target on shares of Immuneering from $20.00 to $8.00 and set a "buy" rating on the stock in a research report on Tuesday, April 2nd. Oppenheimer reaffirmed an "outperform" rating and set a $25.00 price objective on shares of Immuneering in a research note on Tuesday, March 5th. Finally, Needham & Company LLC cut their target price on shares of Immuneering from $20.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 15th.

Immuneering Trading Up 3.3 %

NASDAQ:IMRX traded up $0.07 during mid-day trading on Tuesday, hitting $2.19. The company's stock had a trading volume of 396,383 shares, compared to its average volume of 571,348. The company has a market capitalization of $64.12 million, a price-to-earnings ratio of -1.16 and a beta of -0.89. Immuneering has a fifty-two week low of $1.90 and a fifty-two week high of $14.29. The stock has a fifty day moving average of $4.82 and a 200-day moving average of $6.02.

Immuneering (NASDAQ:IMRX - Get Free Report) last released its quarterly earnings data on Friday, March 1st. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.06). On average, equities analysts anticipate that Immuneering will post -1.89 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Ann E. Berman purchased 57,965 shares of the firm's stock in a transaction dated Monday, March 18th. The shares were acquired at an average cost of $2.13 per share, with a total value of $123,465.45. Following the completion of the purchase, the director now directly owns 67,465 shares of the company's stock, valued at $143,700.45. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Ann E. Berman bought 57,965 shares of the company's stock in a transaction dated Monday, March 18th. The stock was bought at an average price of $2.13 per share, for a total transaction of $123,465.45. Following the completion of the transaction, the director now directly owns 67,465 shares in the company, valued at approximately $143,700.45. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Cormorant Asset Management, Lp sold 509,091 shares of the company's stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $3.72, for a total value of $1,893,818.52. Following the transaction, the insider now directly owns 3,695,273 shares in the company, valued at approximately $13,746,415.56. The disclosure for this sale can be found here. Over the last three months, insiders purchased 111,790 shares of company stock valued at $266,645. Insiders own 23.00% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. raised its position in shares of Immuneering by 2.9% during the 4th quarter. Vanguard Group Inc. now owns 1,073,815 shares of the company's stock valued at $7,893,000 after acquiring an additional 29,963 shares during the last quarter. Virtu Financial LLC acquired a new position in Immuneering in the fourth quarter valued at about $84,000. Barclays PLC boosted its holdings in Immuneering by 327.0% during the fourth quarter. Barclays PLC now owns 34,923 shares of the company's stock worth $257,000 after buying an additional 26,744 shares during the last quarter. Nuveen Asset Management LLC boosted its holdings in Immuneering by 8.6% during the fourth quarter. Nuveen Asset Management LLC now owns 44,049 shares of the company's stock worth $324,000 after buying an additional 3,504 shares during the last quarter. Finally, Oracle Alpha Inc. acquired a new position in shares of Immuneering during the 4th quarter worth about $87,000. Institutional investors own 67.65% of the company's stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.